Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan일본에서 백신 접종률이 높은 의료 센터에서 델타 변이형 SARS-CoV-2 감염 증가Article Published on 2022-05-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, [키워드] Asia BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine breakthrough conducted Coverage Delta delta variant Effectiveness HCW HCWs healthcare worker higher risk Increased infection control Japan measure mRNA vaccine of BNT162b2 protocol reported retrospective cohort study rising robust SARS-COV-2 infection SARS-CoV-2 infections Spread Tokyo vaccination vaccination rate Vaccine vaccine effectiveness variant while [DOI] 10.1016/j.vaccine.2022.04.029 PMC 바로가기 [Article Type] Article
Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19COVID-19에 대한 우려의 변종에 대한 백신 효과 연구에 대한 확장된 보고 지침Article Published on 2022-05-112022-09-11 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, [키워드] Abstract COVID-19 Effectiveness Extended Guidance Reporting Reporting standards Vaccine vaccine effectiveness variants variants of concern [DOI] 10.1016/j.vaccine.2022.04.005 PMC 바로가기 [Article Type] Article
Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021우려의 변종 및 예방 접종 이후 시간에 따른 SARS-CoV2 감염의 전파에 대한 백신 효과, 벨기에 접촉 추적, 2021Article Published on 2022-05-112022-09-11 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, [키워드] Ad26 Ad26.COV2.S adjusted affected age Alpha Bayesian Bayesian analysis BNT162b2 ChAdOx1 Characteristics Complete Contact Contact tracing Course COVID19 decrease Delta Effectiveness faster household hybrid Immunity IMPROVE increase in Infection infectiousness initial less mRNA mRNA-1273 mRNA-vaccines Older onward transmission reduced replacement SARS-CoV2 Sex susceptibility Transmission vaccination Vaccine vaccine effectiveness Vaccine-induced immunity Vaccines variant Viral vector Viral vector vaccines VoC waned [DOI] 10.1016/j.vaccine.2022.04.025 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis감염, 증상 및 중증 COVID-19에 대한 SARS-CoV-2 백신 효과: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-05-072022-09-11 Journal: BMC Infectious Diseases [Category] Coronavirus, COVID19(2023년), SARS, 변종, [키워드] 95% CI Ad26 Ad26.COV2.S age approach assessment booster vaccination can be used certainty Cohort studies cohort study completion Controlled controlled trials coronavirus disease COVID-19 database declined defined dependent on development Effectiveness Efficacy Evidence Evolution Evolution of SARS-CoV-2 FIVE Health Organization Immunity individual individuals Infection literature Meta-analysis outcome Primary outcomes public health random-effects model Randomized controlled trial remained representing Risk of bias SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine searched selected severe COVID-19 symptomatic symptomatic COVID-19 systematic review systematic reviews These data vaccination Vaccine vaccine effectiveness variant variants virus waned waning immunity was performed was used World Health Organization [DOI] 10.1186/s12879-022-07418-y PMC 바로가기 [Article Type] Meta-Analysis
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States중증 급성 호흡기 증후군 코로나바이러스 2 메신저 RNA 백신의 효과로 미국에서 코로나바이러스 질병 2019 입원 예방Multicenter Study Published on 2022-05-032022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adults adults hospitalized Analysis black Case-control Control controls coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 Coverage COVID COVID-19 COVID-19 hospitalization effective Effectiveness evaluated highest Hispanic hospitalizations Hospitalized illness onset Immunocompromised Immunosuppressed Immunosuppression increased risk increases in Lineage median age messenger Messenger RNA Moderna mRNA mRNA vaccine mRNA vaccines multicenter outcomes Participants Patient Pfizer-BioNTech Prevent Preventing receipt respiratory RNA SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 vaccination severe acute respiratory syndrome Coronavirus severe coronavirus disease tested the United State The United States United States vaccination Vaccine vaccine dose vaccine effectiveness Vaccines variant virus with COVID-19 [DOI] 10.1093/cid/ciab687 PMC 바로가기 [Article Type] Multicenter Study
Development of the India COVID-19 vaccine trackerArticle Published on 2022-05-012023-07-10 Journal: The Indian journal of medical research [Category] COVID19(2023년), [키워드] COVID-19 CoWIN India vaccine effectiveness vaccine tracker. [DOI] 10.4103/ijmr.ijmr_3500_21 PMC 바로가기
Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards modelObservational Study Published on 2022-05-012022-10-05 Journal: Age and Ageing [Category] COVID19(2023년), SARS, 임상, [키워드] adjusted hazard ratio adverse outcome Against BNT162b2 calculated Care COVID-19 COVID-19-related death Cox proportional hazard death defined died dose doses Effectiveness England hazard high risk highest individuals Infection intervals moderate mortality data of BNT162b2 Older older people Positive test positive test result protection provided relative SARS CoV-2 SARS-CoV-2 second dose study period Symptom tested the vaccine vaccination Vaccine vaccine effectiveness [DOI] 10.1093/ageing/afac115 PMC 바로가기 [Article Type] Observational Study
Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipientsResearch article Published on 2022-05-012022-10-05 Journal: Vaccine [Category] COVID19(2023년), SARS, 임상, [키워드] Acute kidney injury acute respiratory distress Admission all-cause mortality BNT162b2 case-control study Clinical outcome clinician Complication control group CoronaVac COVID COVID-19 COVID-19 vaccine Cytokine storm death decrease described diagnosed diagnosed with COVID-19 died difference dose Effectiveness Efficacy Endpoint Evidence excluded fatal disease FIVE Follow-up Hospitalization Hospitalized ICU in healthy individuals intensive care kidney transplant kidney transplant recipient kidney transplant recipients Kidney transplantation material median age men nine Occurrence participant Patient patients Prevent Protective Result SARS-CoV-2 SARS-COV-2 infection syndrome the patient the vaccine Treatment Vaccine vaccine effectiveness with COVID-19 [DOI] 10.1016/j.vaccine.2022.04.066 [Article Type] Research article
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021유럽에서 델타 순환이 우세한 동안 1차 진료 및 지역사회 수준에서 COVID-19에 대한 완전한 1차 백신 접종의 효과: 다중 센터 분석, I-MOVE-COVID-19 및 ECDC 네트워크, 2021년 7월~8월Multicenter Study Published on 2022-05-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI acute respiratory symptom acute respiratory symptoms Analysis circulation Community Complete Course COVID-19 COVID-19 vaccine Delta delta variant ECDC Effectiveness Europe European country janssen multicentre multicentre study Older predominant primary care Sample size SARS-CoV-2 symptomatic symptomatic infection test-negative design tested the SARS-CoV-2 the vaccine vaccination vaccination against COVID-19 Vaccine vaccine effectiveness while with COVID-19 [DOI] 10.2807/1560-7917.ES.2022.27.21.2101104 PMC 바로가기 [Article Type] Multicenter Study
mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 20222022년 2월부터 3월까지 슬로베니아의 실제 감시 데이터에서 추정된 오미크론 변이가 우세한 동안 중증 급성 호흡기 감염(SARI) COVID-19로 인한 입원에 대한 mRNA 백신 효과Article Published on 2022-05-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Acute respiratory infection age COVID-19 doses Effectiveness hospitalisation individual mRNA mRNA vaccine mRNA vaccines omicron Omicron variant respiratory infection SARI SARS-CoV-2 severe acute respiratory infection (SARI) Slovenia Surveillance surveillance data Vaccine vaccine effectiveness variant [DOI] 10.2807/1560-7917.ES.2022.27.20.2200350 PMC 바로가기 [Article Type] Article